{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:58:14Z","timestamp":1792148294509,"version":"4.4.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1,15]]},"DOI":"10.1097\/tp.0b013e318279090c","type":"journal-article","created":{"date-parts":[[2012,12,8]],"date-time":"2012-12-08T11:34:39Z","timestamp":1354966479000},"page":"215-221","source":"Crossref","is-referenced-by-count":30,"title":["Sirolimus and Cardiovascular Disease Risk in Liver Transplantation"],"prefix":"10.1097","volume":"95","author":[{"given":"Greg J.","family":"McKenna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Klintmalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Onaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Saracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon F.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran B.","family":"Klintmalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-31-20210129","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.2174\/138161210794454923","article-title":"Sirolimus and its analogs and its effects on vascular diseases.","volume":"16","author":"Adelman","year":"2010","journal-title":"Curr Pharm Des"},{"key":"R2-31-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosisan inflammatory disease.","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-31-20210129","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis.","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"R4-31-20210129","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","article-title":"Rapamune (RAPA, rapamycin, sirolimus): mechanism of action of immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.","volume":"31","author":"Sehgal","year":"1998","journal-title":"Clin Biochem"},{"key":"R5-31-20210129","doi-asserted-by":"crossref","first-page":"H1646","DOI":"10.1152\/ajpheart.00492.2009","article-title":". Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells.","volume":"298","author":"Ma","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R6-31-20210129","doi-asserted-by":"crossref","first-page":"H2721","DOI":"10.1152\/ajpheart.01174.2006","article-title":". Anti-atherosclerotic effects of sirolimus on human vascular smooth muscles cells.","volume":"292","author":"Ma","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R7-31-20210129","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1034\/j.1600-6143.2003.00094.x","article-title":". Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice.","volume":"3","author":"Elloso","year":"2003","journal-title":"Am J Transplant"},{"key":"R8-31-20210129","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1111\/j.1523-1755.2005.09315.x","article-title":"Cardiovascular risk profile in patients treated with sirolimus after renal transplantation.","volume":"93","author":"Morales","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"R9-31-20210129","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1034\/j.1600-6143.2002.20610.x","article-title":"Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model.","volume":"2","author":"Blum","year":"2002","journal-title":"Am J Transplant"},{"key":"R10-31-20210129","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00063030-200115040-00006","article-title":"Risk factors for management of post-transplantation cardiovascular disease.","volume":"15","author":"Fellstrom","year":"2001","journal-title":"Biodrugs"},{"key":"R11-31-20210129","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1681\/ASN.V71158","article-title":". Cardiovascular disease after renal transplantation.","volume":"7","author":"Kasiska","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"R12-31-20210129","first-page":"853","article-title":"Coronado BE, et al..","volume":"32","author":"Levey","year":"1998","journal-title":"Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know What do we need to learn Where do we go from here Am J Kidney Dis"},{"key":"R13-31-20210129","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1161\/CIRCULATIONAHA.105.169180","article-title":". Managing abnormal blood lipids.","volume":"112","author":"Fletcher","year":"2005","journal-title":"Circulation"},{"key":"R14-31-20210129","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1476-5381.2008.00080.x","article-title":". Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor.","volume":"156","author":"Zhao","year":"2009","journal-title":"Br J Pharmacol"},{"key":"R15-31-20210129","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1172\/JCI119038","article-title":". Rapamycin inhibits vascular smooth muscle cell migration.","volume":"98","author":"Poon","year":"2005","journal-title":"J Clin Invest"},{"key":"R16-31-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2003.09.003","article-title":". Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27Kip1-independent pathway.","volume":"172","author":"Castro","year":"2004","journal-title":"Atherosclerosis"},{"key":"R17-31-20210129","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/01.fjc.0000177985.14305.15","article-title":". Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis.","volume":"46","author":"Pakala","year":"2005","journal-title":"J Cardiovasc Pharm"},{"key":"R18-31-20210129","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jps.20751","article-title":". The pharmacodynamics effects of sirolimus and sirolimus-calcineurin inhibitor combinations on macrophage scavenger and nuclear hormone receptors.","volume":"96","author":"Mathis","year":"2007","journal-title":"J Pharm Sci"},{"key":"R19-31-20210129","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.carpath.2007.05.007","article-title":". Risk factors for atherosclerosis and the development of preatherosclerotic intimal hyperplasia.","volume":"16","author":"Cizek","year":"2007","journal-title":"Cardiovasc Pathol"},{"key":"R20-31-20210129","doi-asserted-by":"crossref","first-page":"C507","DOI":"10.1152\/ajpcell.00201.2003","article-title":". The mTORp70S6k1 pathway regulates vascular smooth muscle cell differentiation.","volume":"286","author":"Martin","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"key":"R21-31-20210129","first-page":"430","article-title":". Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and non-immune cells.","volume":"27","author":"Morris","year":"1995","journal-title":"Transplant Proc"},{"key":"R22-31-20210129","first-page":"1989","article-title":"The growth suppressor p27 (Kip1) protects against diet-induced atherosclerosis.","volume":"11","author":"Diez-Juan","year":"2001","journal-title":"FASEB J"},{"key":"R23-31-20210129","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/00007890-199306000-00037","article-title":". Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury: its effects on cellular, growth factor, and cytokine responses in injured vessels.","volume":"55","author":"Gregory","year":"1993","journal-title":"Transplantation"},{"key":"R24-31-20210129","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/00005344-199906000-00001","article-title":". Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin.","volume":"33","author":"Burke","year":"1999","journal-title":"J Cardiovasc Pharmacol"},{"key":"R25-31-20210129","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/TP.0b013e3181e8a699","article-title":". Murine cytomegalovirus infection leads to increased levels of transplant arteriosclerosis in a murine aortic allograft model.","volume":"90","author":"Heim","year":"2010","journal-title":"Transplantation"},{"key":"R26-31-20210129","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1161\/01.RES.75.2.214","article-title":". Active cytomegalovirus infection of arterial smooth muscle cells in immunocompromised rats. A clue to herpesvirus-associated atherogenesis.","volume":"75","author":"Persoons","year":"1994","journal-title":"Circ Res"},{"key":"R27-31-20210129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0140-6736(96)98005-8","article-title":". The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus.","volume":"348","author":"Epstein","year":"1996","journal-title":"Lancet"},{"key":"R28-31-20210129","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJM199608293350903","article-title":". Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy.","volume":"335","author":"Zhou","year":"1996","journal-title":"New Engl J Med"},{"key":"R29-31-20210129","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1128\/JVI.02733-09","article-title":"Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication.","volume":"84","author":"Moorman","year":"2010","journal-title":"J Virol"},{"key":"R30-31-20210129","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/TP.0b013e31824810e6","article-title":". Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.","volume":"93","author":"Nashan","year":"2012","journal-title":"Transplantation"},{"key":"R31-31-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000265166","article-title":". Doxorubicin cardiomyopathy.","volume":"115","author":"Chatterjee","year":"2010","journal-title":"Cardiology"},{"key":"R32-31-20210129","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":". General cardiovascular risk profile for use in primary care: the Framingham Heart Study.","volume":"117","author":"DAgostino","year":"2008","journal-title":"Circulation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0b013e318279090c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T21:16:34Z","timestamp":1643836594000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201301150-00031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,15]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e318279090c","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1,15]]}}}